Overview

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 29 or less days during the 30 days prior to the start of signing consent.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Treatments:
Bupropion
Methamphetamine